CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study
Received 7 April 2018
Accepted for publication 3 May 2018
Published 3 July 2018 Volume 2018:10 Pages 1791—1798
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Nakshatri
Pengtao Yang,1,* Meng Wang,1,* Tian Tian,1,* Yanjing Feng,2 Yi Zheng,1 Tielin Yang,3 Hongtao Li,4 Shuai Lin,1 Peng Xu,1 Yujiao Deng,1 Qian Hao,1 Na Li,1 Feng Guan,5 Zhijun Dai1
1Department of Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, People’s Republic of China; 2Department of Cardiology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710004, People’s Republic of China; 3School of Life Science and Technology, Xi’an Jiaotong University, Xi’an 710049, People’s Republic of China; 4Department of Breast, Head and Neck Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumchi, 830000, People’s Republic of China; 5College of Life Science and Technology, Northwest University, Xi’an 710069, People’s Republic of China
*These authors contributed equally to this work
Introduction: CYP17 is the second most important enzyme in estradiol synthesis. Epidemiological studies have shown the associations between CYP17 polymorphisms and cancer risk. We conducted a case–control study to evaluate the relationship between CYP17 polymorphisms (rs743572 and rs2486758) and breast cancer (BC) risk.
Patients and methods: This case–control study included 560 BC patients and 583 age-matched healthy controls from Northwest China. Two polymorphisms (rs743572 and rs2486758) of CYP17 were genotyped by using Sequenom MassARRAY. ORs and 95% CIs were used to evaluate the relationship.
Results: Compared with the wild genotype of rs743572, we found a significantly reduced risk of BC associated with the variant genotypes (heterozygote model: OR=0.69, 95% CI=0.53–0.89; homozygote model: OR=0.68, 95% CI=0.49–0.95; dominant model: OR=0.69, 95% CI=0.54–0.87; overdominant model: OR=0.78, 95% CI=0.62–0.98; allele model: OR=0.79, 95% CI=0.66–0.93). For rs2486758 polymorphism, we did not find any difference in any of the genetic models. Further stratification analysis by clinical characteristics showed rs743572 was associated with estrogen receptor status (heterozygote model: OR=2.13, 95% CI=1.47–3.08; homozygote model: OR=3.29, 95% CI=1.94–5.58; dominant model: OR=2.39, 95% CI=1.69–3.37) and progesterone receptor status (homozygote model: OR=3.17, 95% CI=1.82–5.55), but there was no association between rs2486758 and clinical characteristics of BC. Haplotype analysis showed that Grs743572Crs2486758 haplotype was a protective factor of BC (OR=0.52, 95% CI=0.40–0.67). Survival analysis did not find that CYP17 rs743572 polymorphism was associated with triple-negative BC, either in terms of overall survival or progression-free survival.
Conclusion: Our results suggest that CYP17 polymorphisms may reduce the susceptibility to BC in Chinese women.
Keywords: CYP17, polymorphism, breast cancer, susceptibility
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]